Cancer name HER2-Positive Breast Cancer
Cancer Type BRCA
Immunotherapy type Oncolytic viruses
Treatment Ad5/3-Δ24-tras
Drugstatus NA
Drugbank ID NA
Checkpoints NA
Signature Type Cell
Signature CD11c+ CD80+ CD40+ cells
Official Symbol Myeloid dendritic cell
Mode of action CE_D_UP
Description for ‘mode of action’:the ‘mode of action’ for signature is composed of three parts: A_B_C. A describes the level at which the corresponding signature changes, it may contain the following values: TRAN(translation), PROT(protein), CE(cell), METH(methylation), AC(acetylation), PHOS(phosphorylation), MU(mutation), SNP(single nucleotide polymorphism), GLYC(glycosylation) and PATH(pathway). B describes the corresponding signature in which cancer immunotherapy condition group has changed, it may contain the following values: R (immunotherapy response group), NR(immunotherapy non-response group), D (Immunotherapy group), ND (No immunotherapy group). C describes the change detail (specific direction) of the corresponding signature, it may contain the following values: UP (High gene/protein expression or increased cellular abundance or enhanced epigenetic modification), DN (Low gene/protein expression or reduced cellular abundance or attenuated epigenetic modifications), LOSS (deletion mutation), GAIN (gain mutation),Other. For example, the search/browse detail result for CD274 was “PROT_R_UP”, it can be interpreted that the protein level of CD274 was upregulated in immunotherapy response individuals.
Experimental mouse model
Description Subpopulation analysis using DC-maturation markers CD80 and CD40 revealed thatAd5/3-Δ24-tras induced significant DC activation :Triple-positive CD11c+CD80+CD40+cells capable of antigen presentation were the most abundant in the Ad5/3-Δ24-trasgroup, representing over 25% of the total population (P<U+00BC>0.047, as compared with mock).
PMID 27458139
Title Oncolytic Adenovirus Expressing Monoclonal Antibody Trastuzumab for Treatment of HER2-Positive Cancer